Latest News

Market capOver $50M
SectorsAll
Filter by sector
Wednesday, October 21, 2026· 10634 stock ideas· 218 writers·
21,139 views· 9,932 clicks

Vicor Update, Part Three

Vicor’s $66.6 million in AI power-delivery royalties generated about $50 million of operating profit, eclipsing its module business as revenue reached $197.1 million.

From X

@kevin__mak

Kevin Mak on X

$NKTR Lots of funky action in this name the past few days, some specific to the ongoing court case and some from bio as a whole. Let's unpack it. The jury note, paraphrased as "Is there a difference between breach + $1 and no breach + $0?", spooked the market and sent the stock down sharply. Two sides to this. First, the note is informative, but only a little. It tells us at least one juror sees the $0/$1 outcome as part of their possible resolution space. Where I think the market (or at least fintwit) got it wrong is treating the note as the voice of the entire jury. It could reflect the whole panel, or it could be a single juror's question. It doesn't even tell us direction: it could come from a juror looking for a way to find breach despite doubting the damages case. The price action implied the whole jury is now choosing between $0 and $1, which I think is a big overread. Second, this is NKTR: a retail/fintwit-heavy, relatively illiquid SMID-cap biotech that moves 5% on a random Tuesday with no news. A 10% move on this headline looks extreme, but near-term price action here mostly reflects value-agnostic traders playing local news and liquidity flow, not a considered repricing of long-term value. The bigger picture: the case is largely a distraction from the real value, which is Rezpeg. I'm not a biotech expert, but the sell side and most biotech specialists I respect see it as a likely viable commercial product that's underpriced here. If anything, the case matters mainly as an overhang. An uncertain $0-to-$1B+ claim is hard for any acquirer or partner to price, so resolution in almost any direction clears the path for corporate action. The distraction is creating the opportunity. Disclosure: Creek Drive and its affiliated funds holds a long position in NKTR. Views expressed are current opinions for information only, subject to change and are not investment advice or a recommendation to buy or sell any security. Investing involves the risk of loss and past performance is not indicative of future performance. See the disclosures link in my bio for more important information.

Free Recaps of the best new stock ideas, delivered every morning.

Carecloud News

CareCloud may attract a private-equity buyer after its Q3 call, with acquiring enough shares the main obstacle to a take-private deal.

Heico Corporation

HEICO sells FAA-approved aircraft replacement parts at 30% to 50% discounts to OEMs, gaining customers as restrictive aftermarket contracts…

CHGG · long

Chegg Inc

Chegg is framed as a binary long with 500% upside against 20% downside.

Copper Fox Metals: Research Flash

Copper Fox’s C$9.1 million Schaft Creek program advances metallurgical, tailings, water and road studies toward a pre-feasibility study,…

AppLovin Deep Dive

AppLovin rebuilt its ad model with AXON 2.0, lifting LTM revenue to about $7 billion and margins to 77% as Unity competition threatens ad…

Have a source we’re missing? Send your pick

Recent recaps

Publications we follow

Every publication on this site, hand-picked.

128 publications

Newsletters 108

X accounts we follow

Every account on this site, hand-picked.

90 accounts

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.

Anything we’re missing?

Send us a pick